Selected Publications

Narayan, V.; Keefe, S.; Haas, NB.; Wang, L.; Puzanov, I.; Putt, M.; Catino, A.; Fang, J.; Agarwal, N.; Hyman, D.; Smith, AM.; Finkelman, B.; Narayan, HK.; Ewer, S.; ElAmm, C.; Lenihan, D.; Ky, B.: Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma. Clin Cancer Res 23(14): 3601-3609, Jul 2017.

Narayan V, Barber-Rotenberg JS, Jung IY, Lacey SF, Rech AJ, Davis MM, Hwang WT, Lal P, Carpenter EL, Maude SL, Plesa G, Vapiwala N, Chew A, Moniak M, Sebro RA, Farwell MD, Marshall A, Gilmore J, Lledo L, Dengel K, Church SE, Hether TD, Xu J, Gohil M, Buckingham TH, Yee SS, Gonzalez VE, Kulikovskaya I, Chen F, Tian L, Tien K, Gladney W, Nobles CL, Raymond HE; Prostate Cancer Cellular Therapy Program Investigators; Hexner EO, Siegel DL, Bushman FD, June CH, Fraietta JA, Haas NB.: PSMA-targeting TGFβ-insensitive Armored CAR T-cells in Metastatic Castration Resistant Prostate Cancer: a Phase 1 Trial. Nat Med 28(4): 724-734, Apr 2022.

Dorff TB, Narayan V, Forman SJ, Zang PD, Fraietta JA, June CH, Haas NB, Priceman SJ.: Novel Redirected T Cell Immunotherapies for Advanced Prostate Cancer. Clin Cancer Res 28(4): 576-584, Oct 2021 Notes: * Co-First Authors (In Press).

Jonasch E, Donskov F, Iliopolous O, Rathmell WK, Narayan V, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini R, Linehan WM, Srinivasan R.: Belzutifan for Von Hippel-Lindau Disease–Associated Renal Cell Carcinoma. New Engl J Medicine 385(22): 2036-2046, Nov 2021.

Pal SK, Tangen C, Thompson IM Jr, Balzer-Haas N, George DJ, Heng DYC, Shuch B, Stein M, Tretiakova M, Humphrey P, Adeniran A, Narayan V, Bjarnason GA, Vaishampayan U, Alva A, Zhang T, Cole S, Plets M, Wright J, Lara PN Jr.: A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet. (eds.). 397(10275): 695-703, Feb 2021.

Sharma P, Pachynski RK, Narayan V, Fléchon A, Gravis G, Galsky MD, Mahammedi H, Patnaik A, Subudhi SK, Ciprotti M, Simsek B, Saci A, Hu Y, Han GC, Fizazi K.: Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial. Cancer Cell 38(4): 489-499, Oct 2020.

Narayan, V.; Harrison, M.; Cheng, H.; Kenfield, S.; Aggarwal, R.; Kwon, D.; McKay, R.; Hauger, R.; Hart, N.; Conzen, S.; Borno, H.; Jim, H.; Dicker, A.; Dorff, T.; Moslehi, J.; Mucci, L.; Parsons, JK.; Saad, F.; Soule, H.; Morgans, A.; Ryan, CJ.: Improving Research for Prostate Cancer Survivorship: A Statement from the SuRECaP (Survivorship Research in Prostate Cancer) Working Group. Urologic Oncology: Seminars and Original Investigations 38(3): 83-93, Mar 2020.

Narayan, V.; Puligandla, M.; Haas, NB.; Subramanian, P.; DiPaola, RS.; Uzzo, R.: Patterns of Relapse and Implications for Post-Nephrectomy Surveillance for Patients with High-Risk Non-Clear Cell Renal Cell Carcinoma: Subgroup Analysis of the Phase 3 ECOG-ACRIN E2805 Trial. J Urol 201(1): 62-68, Jan 2019.

Narayan, V.; Vapiwala, N.; Mick, R.; Subramanian, P.; Christodouleas, J.; Bekelman, J.; Deville, C.; Rajendran, R.; Haas, NB.: Phase I Trial of Everolimus and Radiation Therapy for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy. Int J Radiat Oncol Biol Phys 97(2): 355-361, Feb 2017.

Yu E, Narayan V, Esposito G, Szmulewitz R, Lu Y, Lilly MB, Calais J, Bratslavsky G, Menda Y, Vasanawala M, Pouliot F, Laidley D, Fleshner N, Saad F, Provost JC, Teslenko I, Rawat NK, Ulaner G.: 131I-LNTH-1095 Radioligand Therapy Plus Enzalutamide vs. Enzalutamide Alone in Men With PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Study. Clin Canc Res 15(32(10)): 1973-1982, May 2026.

Jung IY, Bartoszek RL, Rech AJ, Collins SM, Ooi SK, Williams EF, Hopkins CR, Narayan V, Haas NB, Frey NV, Hexner EO, Siegel DL, Plesa G, Porter DL, Cantu A, Everett JK, Guedan S, Berger SL, Bushman FD, Herbst F, Fraietta JA.: Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T cell-intrinsic Dysfunction. Cancer Discov 13(7): 1636-1655, Jul 2023.

Jung IY, Narayan V, McDonald S, Rech AJ, Bartoszek R, Hong G, Davis MM, Xu J, Boesteanu AC, Barber-Rotenberg JS, Plesa G, Lacey SF, Jadlowsky JK, Siegel DL, Hammill DM, Cho-Park PF, Berger SL, Haas NB, Fraietta JA.: BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion. Sci Transl Med 14(670): doi: 10.1126/scitranslmed.abn7336. Nov 2022.

Schram AM, Colombo N, Arrowsmith E, Narayan V, Yonemori K, Scambia G, Zelnak A, Bauer TM, Jin N, Ulahannan SV, Colleoni M, Aftimos P, Donoghue MTA, Rosen E, Rudneva VA, Telli ML, Domchek SM, Galsky MD, Hoyle M, Chappey C, Stewart R, Blake-Haskins JA, Yap TA.: Avelumab Plus Talazoparib in BRCA1/2- or ATM-Altered Advanced Solid Tumors (JAVELIN BRCA/ATM): Results From an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial. JAMA Oncology 17(1): e225218, Nov 2022.

Narayan V, Ross AE, Parikh RB, Nohria A, Morgans AK.: How to Treat Prostate Cancer With Androgen Deprivation and Minimize Cardiovascular Risk: A Therapeutic Tightrope. J Am Coll Cardiol CardioOnc 3(5): 737-741, Dec 2021.

Narayan V.: Comparing Cardiovascular Outcomes with Degarelix or Leuprolide as Prostate Cancer Therapy -- Applying Real-World Data to Clinical Trial Emulation. JAMA Netw Open 4(10): e2131429. Oct 2021.

Sun L, Parikh RB, Hubbard RA, Cashy J, Takvorian SU, Vaughn DJ, Robinson KW, Narayan V, Ky B.: Assessment and Management of Cardiovascular Risk Factors Among US Veterans With Prostate Cancer. JAMA Netw Open 4(2): e210070, Feb 2021 Notes: *Co-Senior Authors.

Ravi, P.; Mantia, C.; Su, C.; Sorenson, K.; Elhag, D.; Rathi, N.; Bakouny, Z.; Agarwal, N.; Zakharia, Y.; Costello, BA.; McKay, RR.; Narayan, V.; Alva, A.; McGregor, BA.; Gao, X.; McDermott, DF.; Choueiri, TK.: Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma. JAMA Oncology 6(10): 1606-1610, Oct 2020.

Narayan V, Thompson EW, Demissei B, Ho JE, Januzzi JL, Ky B.: Mechanistic Biomarkers Informative of Both Cancer and Cardiovascular Disease. J Am Coll Cardiology 75(21): 2726-2737, Jun 2020.

Chanzá, NM.; Xie, W.; Bilen, MA.; Dzimitrowicz, H.; Burkart, J.; Geynisman, DM.; Balakrishnan, A.; Bowman, IA.; Jain, R.; Stadler, W.; Zakharia, Y.; Narayan, V.; Beuselinck, B.; McKay, R.; Tripathi, A.; Pachynski, R.; Hahn, AW.; Hsu, J.; Shah, SA.; Lam, ET.; Rose, TL.; Mega, AE.; Vogelzang, N.; Harrison, MR.; Mortazavi, A.; Plimack, ER.; Vaishampayan, U.; Hammers, H.; George, S.; Haas, N.; Agarwal, N.; Pal, SK.; Srinivas, S.; Carneiro, BA.; Heng, D.; Bosse, D.; Choueiri, T.; Harshman, LC. : Cabozantinib in advanced non-clear cell renal carcinoma: a multicenter retrospective cohort analysis. Lancet Oncol 20(4): 581-590, Apr 2019.

Narayan, V.; Ky, B.: Common Cardiovascular Complications of Cancer Therapy: Epidemiology, Risk Prediction, and Prevention. Annu Rev Med 69(1): 97-111, Jan 2018.

Finkelman, BS., Putt, M., Wang, T., Wang, L., Narayan, H., Domchek, S., DeMichele, A., Fox, K., Matro, J., Shah, P., Clark, A., Bradbury, A., Narayan, V., Carver, J., Tang, WH., Ky, B.: Arginine-Nitric Oxide Metabolites and Cardiac Dysfunction in Patients with Breast Cancer. J Am Coll Cardiology 70(2): 152-162, Jul 2017.

Narayan, V., Haas, N.: Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives. Int J Nephrol 9: 65-72, Mar 2016.

Pepin, A.; Doucette, A.; Narayan, V.; Maxwell, KN.; Takvorian, SU.; O'Brien, SR.; Mankoff, DA.; Mulugeta, PG.; Taunk NK.: Differential Response to (177)Lu-PSMA-617 in Patients with Tumor Suppressor Gene-Mutated Metastatic Castration-Resistant Prostate Cancer. J Nucl Med Page: jnumed.125.270757, Feb 2026.

McKay RR, Maughan BL, Morgans AK, Shore ND, Yu EY, Madan RA, Berchuck JE, Carthon BC, Finkelstein SE, Gomella L, Gorin MA, Hahn AW, Loeb S, Narayan V, Petrylak DP, Ryan CJ, Tawagi K, Tran PT, Dorff T.: Evolving Strategies in Prostate Cancer: Emerging Approaches and Unmet Needs from the Bridging the Gaps in Prostate Cancer Expert Panel. Cancer 132(4): e70304, Feb 2026.

Srinivasan R, Iliopoulos O, Beckermann KE, Narayan V, Maughan BL, Oudard S, Else T, Maranchie JK, Iversen AB, Cornell J, Perini RF, Liu Y, Linehan WM, Jonasch E.: Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study. Lancet Oncol 26(5): 571-582, May 2025 Notes: doi: 10.1016/S1470-2045(25)00099-3.

Iliopoulos O, Iversen AB, Narayan V, Maughan BL, Beckermann KE, Oudard S, Else T, Maranchie JK, Goldberg CM, Fu W, Perini RF, Liu Y, Linehan WM, Srinivasan R, Jonasch E.: Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study. Lancet Oncol 25(10): 1325-1336. Oct 2024 Notes: PMC11951471 (available on 2025-10-01)

Eule CJ, Hu J, Al-Saad S, Collier K, Boland P, Lewis AR, McKay RR, Narayan V, Bosse D, Mortazavi A, Rose TL, Costello BA, Bryce AH, Lam ET. : Outcomes of Second-Line Therapies in Patients with Metastatic de Novo and Treatment-Emergent Neuroendocrine Prostate Cancer: A Multi-Institutional Study. Clin Genitourin Cancer 21(4): 483-490, Aug 2023.

Demissei, B.; Finkelman, B.; Hubbard, RA.; Zhang, L.; Smith, AM.; Sheline, K.; McDonald, C.; Narayan, HK.; Narayan, V.; Waxman, AJ.; Domchek, S.; DeMichele, A.; Shah, P.; Clark, A.; Bradbury, A.; Carver, J.; Upshaw, J.; Armenian, SH.; Liu, P.; Ky, B. : Detailed Phenotyping Reveals Distinct Trajectories of Cardiovascular Function and Symptoms with Exposure to Modern Breast Cancer Therapy. Cancer 125(16): 2762-2771, Aug 2019.

Mohiuddin, J.; Narayan, V.; Venigalla, S.; Vapiwala, N. : Variations in patterns of concurrent androgen deprivation therapy use based on dose escalation with external beam radiotherapy vs. brachytherapy boost for prostate cancer. Brachytherapy 18(3): 322-331, May 2019.

Narayan, V.; Gunnarsson, O.; Hwang, WT.; Nathanson, KL.; Stadtmauer, EA.; Vaughn, DJ.: Risk-Stratified Initial Salvage Therapy for Relapsed or Refractory Metastatic Germ Cell Tumor. Clin Genitourin Cancer 14(6): 524-529, Dec 2016.

Narayan, V.; Mamtani, R.; Keefe, S.; Guzzo, T.; Malkowicz, SB.; Vaughn, DJ.: A Phase II Study of Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer. Cancer Res Treat 48(3): 1084-91, Jul 2016.

von Amsberg G, Bulkley A, DeCongelio M, Skiles G, Grisolano J, Yang, L, Masurkar N, Morasso C, Costanza-McDonald S, Yin X, Teitsson S, Patel MY, Narayan V. : Treatment Patterns Among Androgen Receptor Pathway Inhibitor-Experienced Patients with Metastatic Castration-Resistant Prostate Cancer: A Global Real-world Study. Clin Genitourin Cancer 24(3), Apr 2026.

Narayan V, Patel MY, Teitsson S, Rosenblatt L, Yin X, Pivneva I, Gao S, Sundar M, Betts KA.: Treatment Patterns and Survival Outcomes Among Androgen Receptor Pathway Inhibitor-Experienced Patients With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer 22(6): 10.1016/j.clgc.2024.102188. Aug 2024.

Welch E, Guerraty MA, Demissei BG, Haas N, Takvorian S, Parikh RB, Vaughn DJ, Pryma D, Mankoff DA, Ky B, Narayan V. : Coronary Microvascular Dysfunction in Men with Prostate Cancer Receiving Androgen-Deprivation Therapy. Clin Genitourin Cancer 22(4): 102107. Aug 2024.

Breen KE, Symecko H, Spielman K, Gebert R, Shah IH, Pundock S, Batson M, Narayan VK, Stadler ZK, Autio KA, Abida W, Danila DC, Scher HI, Morris MJ, Hamilton JG, Robson ME, Domchek SM, Carlo MI.: Clinical Impact of a Rapid Genetic Testing Model for Advanced Prostate Cancer Patients. J Urol 209(5): 918-27, May 2023.

Pain DJ, Takvorian SU, Narayan V.: Disparities in Clinical Care and Research in Renal Cell Carcinoma. Kidney Cancer 6(3): 147-157, July 2022.

Barrett M, Wilcox NS, Huang A, Levy R, Demissei B, Narayan V, Ky B.: Bearing Allostatic Load: Insights into a More Equitable Future Within Cardio-Oncology. Trends Mol Medic 28(12): 1040-1049, Dec 2022.

Lee DJ, Hausler R, Le AN, Kelly G, Powers J, Ding J, Feld E, Desai H, Morrison C, Doucette A, Gabriel P, Genetics Center R, Judy RL, Weaver J, Kember R, Damrauer SM, Rader DJ, Domchek SM, Narayan V, Schwartz LE, Maxwell KN.: Association of inherited mutations in DNA repair genes with localized prostate cancer Eur Urol 81(6): 559-567, Jun 2022.

Hamilton JG, Symecko H, Spielman K, Breen K, Mueller R, Catchings A, Trottier M, Salo-Mullen EE, Shah I, Arutyunova A, Batson M, Gebert R, Pundock S, Schofield E, Offit K, Stadler ZK, Cadoo K, Carlo MI, Narayan V, Reiss KA, Robson ME, Domchek SM.: Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer. Genet Med 23(11): 2105-2113, Nov 2021.

Morris MJ, Rowe SP, Gorin MA, Saperstein L, Pouliot F, Josephson D, Wong JYC, Pantel AR, Cho SY, Gage KL, Piert M, Iagaru A, Pollard JH, Wong V, Jensen J, Lin T, Stambler N, Carroll PR, Siegel BA; CONDOR Study Group.: Diagnostic Performance of 18 F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase 3, Multicenter Study. Clin Cancer Res 27(13): 3674-3682, Feb 2021 Notes: CONDOR Study Group.

Narayan, V.; Morgans, AK.: Duration of Androgen Deprivation Therapy and Cardiovascular Fitness: Right Patient, Right Therapy, Right Time. JACC: CardioOncol 2(4): 564-566, Nov 2020.

Demissei BG; Finkelman B; Hubbard RA; Smith AM; Narayan HK; Narayan V; Shah P; Waxman AJ; Domchek SM; Ky B.: Cardiovascular Function Phenotypes in Response to Cardiotoxic Breast Cancer Therapy. J Am Coll Cardiology 73(2): 248-249, Jan 2019.

Zhang, KW; Finkelman, BS; Gulati, G; Narayan, HK; Upshaw, J; Narayan, V; Plappert, T; Englefield, V; Smith, AM; Zhang, C; Hundley, WG; Ky B.: Abnormalities in 3-Dimensional Left Ventricular Mechanics With Anthracycline Chemotherapy Are Associated With Systolic and Diastolic Dysfunction. JACC Cardiovasc Imaging 11(8): 1059-1068, Aug 2018.

Narayan, V.; Hwang, WT.; Lal, P.; Rosen, M.; Gallagher, M.; O'Dwyer, P.; Vaughn, DJ.: Cyclin-Dependent Kinase 4/6 Inhibition for the Treatment of Mature Teratoma: Long-term Follow-up of a Phase II Study. Clin Genitourin Cancer 14(6): 504-510, Dec 2016.

Narayan, V.; Deshpande, C.; Bermudez, CA.; Golato, JM.; Lee, J.; Diamond, J.; Vaughn, DJ.: Bilateral Lung Transplantation for Bleomycin-Associated Lung Injury. Oncologist 22(5): 620-622, May 2017.

Narayan, V.; Vaughn, D.: Pharmacokinetic and toxicity considerations in the use of neoadjuvant chemotherapy for bladder cancer. Expert Opin Drug Metab Toxicol 11(5): 731-42, May 2015.

Leong D, Gong S, Sattar N, Narayan V, Reizine NM, Gerstein H, Vellky J.: Incretin Mimetics in Cancer and Cardiovascular Disease: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol 8(1): 1-16, Feb 2026.

Barata P, Tangen C, Plets M, Thompson IM Jr, Narayan V, George DJ, Heng DYC, Shuch B, Stein M, Gulati S, Tretiakova M, Tripathi A, Bjarnason GA, Humphrey P, Adeniran A, Vaishampayan U, Alva A, Zhang T, Cole S, Lara PN Jr, Lerner SP, Balzer-Haas N, Pal SK.: Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma. J Clin Oncol 42(33): 3911-3916. Nov 2024.

Demissei BG, Ko K, Huang A, Lee DJ, Doucette AG, Smith AM, Wilcox NS, Reibel J, Sun L, Agarwal M, Haas NB, Hollis G, Shpilsky JE, Takvorian SU, Vaughn DJ, Chen J, Hubbard RA, Powell-Wiley T, Yancy C, Narayan V, Ky B. : Social Determinants of Health Mediate Racial Disparities in Cardiovascular Disease in Men With Prostate Cancer. JACC: CardioOncology 6(3): 390-401, Jun 2024.

Else T, Jonasch E, Iliopoulos O, Beckermann KE, Narayan V, Maughan BL, Oudard S, Maranchie JK, Iversen AB, Goldberg CM, Fu W, Perini RF, Liu Y, Linehan WM, Srinivasan R.: Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study. Clin Cancer Research 30(9): 1750-1757, May 2024.

Narayan V, Liu T, Song Y, Mitchell J, Sicks J, Gareen I, Sun L, Denduluri S, Fisher C, Manikowski J, Wojtowicz M, Vadakara J, Haas N, Margulies KB, Ky B.: Early Increases in Blood Pressure and Major Adverse Cardiovascular Events in Renal Cell Carcinoma and Thyroid Cancer Patients Treated with VEGFR Tyrosine Kinase Inhibitors. J Natl Compr Canc Netw 21(10): DOI: https://doi.org/10.6004/jnccn.2023.7047, Oct 2023.

Marar M, Long Q, Mamtani R, Narayan V, Vapiwala N, Parikh RB. : Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone. JAMA Netw Open 5(1): e2142093, Jan 2022.

Bratslavsky G, Mendhiratta N, Daneshvar M, Brugarolas J, Ball MW, Metwalli A, Nathanson KL, Pierorazio PM, Boris RS, Singer EA, Carlo MI, Daly MB, Henske EP, Hyatt C, Middleton L, Morris G, Jeong A, Narayan V, Rathmell WK, Vaishampayan U, Lee BH, Battle D, Hall MJ, Hafez K, Jewett MAS, Karamboulas C, Pal SK, Hakimi AA, Kutikov A, Iliopoulos O, Linehan WM, Jonasch E, Srinivasan R, Shuch B.: Genetic Risk Assessment for Hereditary Renal Cell Carcinoma: Clinical Consensus Statement. Cancer 127(21): 3957-3966, Nov 2021.

Feld, E.; Harton, J.; Meropol, NJ.; Adamson, BJS.; Cohen, A.; Parikh, RB.; Galsky, MD.; Narayan, V.; Christodouleas, J.; Vaughn, DJ.; Hubbard, RA.; Mamtani, R.: Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer. Eur Urol 76(4): 524-532, Oct 2019.

Narayan, V.; Vaughn, DJ.; Ky, B.: Cardiovascular Toxicities of Therapy for Genitourinary Malignancies. Urologic Oncology: Seminars and Original Investigations 38(3): 121-128, Mar 2020.

Narayan, V.; Gladney, W.; Plesa, G.; Vapiwala, N.; Carpenter, E.; Maude, SL.; Lal, P.; Lacey, S.; Melenhorst, J.; Sebro, R.; Farwell, M.; Hwang, WT.; Moniak, M.; Gilmore, J.; Lledo, L.; Dengel, K.; Marshall, A.; Coughlin, C.; June, CH.; Haas, NB.: A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer. American Society of Clinical Oncology Genitourinary Cancers Symposium, San Francisco, CA J Clin Oncol 37(suppl 7S; abstr TPS347), Feb 2019 Notes: "Oral Presentation"

Osterman, CK.; Alanzi, J.; Lewis, JD.; Kaufman, EL.; Narayan, V.; Boursi, B.; Vajravelu, RK.; Scott, FI.; Malkowicz, SB.; Mamtani, R.: Association Between Symptomatic Versus Asymptomatic Recurrence and Survival in Bladder Cancer. Clin Genitourin Cancer 16(3): 235-239, Jun 2018.

Rathkopf DE, Patel MR, Choudhury AD, Rasco D, Lakhani N, Hawley JE, Srinivas S, Aparicio A, Narayan V, Runcie KD, Emamekhoo H, Reichert ZR, Nguyen MH, Wells AL, Kandimalla R, Liu C, Suryawanshi S, Han J, Wu J, Arora VK, Pourdehnad M, Armstrong AJ.: Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer. Ann Oncol 36(1): 76-88, Jan 2025.

Parikh RB, Gallo JJ, Wong YN, Robinson KW, Cashy JP, Narayan V, Jayadevappa R, Chhatre S.: Long-term depression incidence and associated mortality among African American and White prostate cancer survivors. Cancer 127((18)): 3476-3485, Sep 2021.

Osterman, CK.; Babu, DS.; Geynisman, D.; Lewis, B.; Somerd, RA.; Balar, AV.; Zibelman, MR.; Guancial, EA.; Antinori, G.; Yu, S.; Narayan, V.; Guzzo, TJ.; Plimack, ER.; Vaughn, DJ.; Fung, C.; Mamtani, R.: Efficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin‐Based Chemotherapy for Muscle‐Invasive Bladder Cancer. Oncologist 24(5): 688-90, May 2019.

Catino, AB; Hubbard, RA; Chirinos, JA; Townsend, R; Keefe, S; Haas, NB; Puzanov, I; Fang, JC; Agarwal, N; Hyman, D; Smith, AM; Gordon, M; Plappert, T; Englefield, V; Narayan, V; Ewer, S; ElAmm, C; Lenihan, D; Ky, B.: Longitudinal Assessment of Vascular Function With Sunitinib in Patients With Metastatic Renal Cell Carcinoma. Circ Heart Fail 11(3): e004408, Mar 2018.

Hsu M, Shan X, Zhang R, Berlin E, Goel A, Agarwal M, Wong YN, Christodouleas JP, Vaughn DJ, Narayan V, Takvorian SU, Vapiwala N, Pantel AR, Haas NB.: Prostate Cancer Recurrence: Examining the Role of Salvage Radiotherapy Field and Risk Factors for Regional Disease Recurrence Captured on 18F-DCFPyL PET/CT. Clin Genitourin Cancer 22(4): 102108. Aug 2024.

Zorko NA, Makovec A, Elliott A, Kellen S, Lozada JR, Arafa AT, Felices M, Shackelford M, Barata P, Zakharia Y, Narayan V, Stein MN, Zarrabi KK, Patnaik A, Bilen MA, Radovich M, Sledge G, El-Deiry WS, Heath EI, Hoon DSB, Nabhan C, Miller JS, Hwang JH, Antonarakis ES.: Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes. Prostate Cancer Prostatic Dis 28(1): 129-137, Mar 2025.

Zarrabi KK, Narayan V, Mille PJ, Zibelman MR, Miron B, Bashir B, Kelly WK.: Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer. Ther Adv Urol 15: 17562872231182219, Jun 2023.

Li, L.; Huang, L.; Vergis, A.; Ye, H.; Bajwa, A.; Narayan, V.; Strieter, R.; Rosin, D.; Okusa, M. : IL-17 produced by neutrophils regulates interferon gamma-mediated neutrophil migration in mouse kidney ischemia-reperfusion injury. J Clin Invest 120(1): 331-42, Jan 2010.

Lin JK, Hearn CM, Getzen E, Long Q, Lee DC, Keaveny TM, Jayadevappa R, Robinson KW, Wong YN, Maxwell KN, Narayan V, Haas NB, Takvorian SU, Bikle DD, Chiang JM, Khan AN, Rajapakse CS, Morgans AK, Parikh RB.: Validation of Biomechanical Computed Tomography for Fracture Risk Classification in Metastatic Hormone-sensitive Prostate Cancer. Eur Urol Oncol S2588-9311(23)00230-4, Nov 2023.

Hahn VS, Zhang KW, Sun L, Narayan V, Lenihan DJ, Ky B.: Heart Failure With Targeted Cancer Therapies: Mechanisms and Cardioprotection. Circ Res 128(10): 1576-1593, May 2021.

Hwang, A.; Narayan, V.; Yang, YX.: Type 2 Diabetes Mellitus and Survival in Pancreatic Adenocarcinoma: A Retrospective Cohort Study. Cancer 119(2): 404-10, Jan 2013.

Demissei, B.; Hubbard, RA.; Zhang, L.; Smith, AM.; Sheline, K.; McDonald, C.; Narayan, V.; Domchek, SM.; DeMichele, A.; Shah, P.; Clark, AS.; Fox, K.; Matro, J.; Bradbury, AR.; Knollman, H.; Getz, KD.; Armenian, SH.; Januzzi, JL.; Tang, W.; Liu, P.; Ky, B.: Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction. J Am Heart Assoc 9(2): e014708, Jan 2020.

Narayan, V.: Metastatic Prostate Cancer. Radiation Oncology: A Question Based Review. Wolters Kluwer, 3rd Edition, Sep 2018.

Taku, N.; Narayan, V.; Wang, X.; Vapiwala, N.: Prevalence, predictors, and implications for appropriate use of active surveillance management among black men diagnosed with low-risk prostate cancer. Am J Clin Oncol 42(6): 507-511, Jun 2019.

Chao, HH.; Feld, EK.; Narayan, V.; Sebro, R.; Jones, JA.: Radiation Recall Myositis Following Carboplatin/Docetaxel Chemotherapy. Pract Radiat Oncol 10(1): e50-e52. Jan 2020.

Demissei BG, Adusumalli S, Hubbard RA, Denduluri S, Narayan V, Clark AS, Shah P, Knollman H, Getz KD, Aplenc R, Carver JR, Ky B.: Cardiology Involvement in Patients With Breast Cancer Treated With Trastuzumab. JACC: CardioOncology 2(2): 179-189, Jun 2020.

Yu S, Le A, Feld E, Schriver E, Gabriel P, Doucette A, Narayan V, Feldman M, Schwartz L, Maxwell K, Mowery D.: A Natural Language Processing-Assisted Extraction System for Gleason Scores: Development and Usability Study. JMIR Cancer 7(3): e27970, Jul 2021.

Thompson EW, Demissei BG, Smith AM, Brahmbhatt P, Wang J, Clark A, DeMichele A, Narayan V, Shah P, Sun L, Lefebvre B, Fradley MG, Carver JR, Tang WHW, Ky B.: Paraoxonase-1 Activity in Breast Cancer Patients Treated With Doxorubicin With or Without Trastuzumab. JACC Basic Transl Sci 7(1): 1-10, Dec 2021.

Herrera CD, Guerra CE, Narayan V, Guzzo TJ, Mamtani R, Lee DJ, Tasian GE, Talwar R.: Financial toxicity in prostate cancer survivors: A national cross-sectional assessment of subjective financial burden. Urologic Oncology: Seminars and Original Investigations S1078-1439(22): 00395-7, Nov 2022.

Narayan V, Jonasch E.: Systemic Therapy Development in Von Hippel–Lindau Disease: An Outsized Contribution from an Orphan Disease. Cancers 14(21): 5313, Oct 2022.

Duarte C, Hu J, Beuselinck B, Panian J, Weise N, Dizman N, Collier KA, Rathi N, Li H, Elias R, Martinez-Chanza N, Rose TL, Harshman LC, Gopalakrishnan D, Vaishampayan U, Zakharia Y, Narayan V, Carneiro BA, Mega A, Singla N, Meguid C, George S, Brugarolas J, Agarwal N, Mortazavi A, Pal S, McKay RR, Lam ET. : Metastatic renal cell carcinoma to the pancreas and other sites — a multicenter retrospective study. eClinMed 60( 102018), Jun 2023.

Orlovskiy S, Gupta PK, Roman J, Arias-Mendoza F, Nelson DS, Koch CJ, Narayan V, Putt ME, Nath K.: Lonidamine Induced Selective Acidification and De-Energization of Prostate Cancer Xenografts: Enhanced Tumor Response to Radiation Therapy. Cancers 16(7): 1384, Mar 2024 Notes: doi: 10.3390/cancers16071384.

Hahn AW, Koutroumpakis E, Narayan V, Aparicio A. : The need for precision medicine in managing cardiovascular risk for men receiving ADT. Prostate Cancer Prostatic Dis 28: 245–246, May 2025.

Orlovskiy S, Gupta PK, Arias-Mendoza F, Singh DK, Nova S, Nelson DS, Narayan V, Koch CJ, Hardy M, You M, Kalyanaraman B, Nath K.: Enhancing Radiation Therapy Response in Prostate Cancer Through Metabolic Modulation by Mito-Lonidamine: A 1H and 31P Magnetic Resonance Spectroscopy Study. Int J Mol Sci 26(2): 509, Jan 2025.

Berlin E, Ko K, Ma L, Messing I, Hollawell C, Smith AM, Taunk NK, Narayan V, Upshaw JN, Clark AS, Shah PD, Knollman H, Bhattacharya S, Koropeckyj-Cox D, Wang J, Yegya-Raman N, Han IS, Lefebvre B, Li T, Wilcox NS, Jung W, Chen J, Freedman GM, Ky B.: Cardiac Effects of Modern Breast Radiation Therapy in Patients Receiving Systemic Cancer Therapy. JACC CardioOncol 7(3): 219-230, Apr 2025.

Cirne F, Sedelaar M, Narayan V, Macedo A, Koo C, de Jesus J, Ng A, Bastos D, Briganti A, Dent SF, Shah NP, Lopes RD, Lenihan DJ, Leong DP.: Principles of Optimal Multidisciplinary Management of Prostate Cancer in Clinical Practice. Cardiooncology 11(1): 28, Mar 2025.

Jung W, Hubbard RA, Smith AM, Ko K, Huang A, Wang J, Isaacs JM, Zhang L, Liu PP, Chen Z, Shah PD, Mintzer D, Bhattacharya S, Knollman HM, Clark AS, Koropeckyj-Cox D, Messinger M, Wilcox NS, Xia C, Narayan V, Upshaw JN, Armenian SH, Ky B.: Risk-guided Cardioprotection with Carvedilol in Patients with Breast Cancer (CCT guide): A Phase 1 Randomized Clinical Trial. Breast Cancer Res Treat 211(2): 293-305, Jun 2025 Notes: doi: 10.1007/s10549-025-07636-3.

Crawford TB, Tayeb M, Barrett E, Al-Saleem T, Kondam P, Hausler R, Symecko H, Orr C, Wolfe C, Mann D, Spielman K, Wong G, Haas N, Narayan V, Robinson K, Takvorian S, Wong YN, Sokolova A, Montgomery RB, Menendez C, Kelley MJ, Aiello LB, Garraway IP, Domchek SM, Maxwell KN.: Pathogenic germline variants in a racially diverse real-world cohort of prostate cancer patients. J Natl Compr Canc Netw Jan 2026.

Pepin A, Doucette A, Vapiwala N, Narayan V, Takvorian SU, O'Brien SR, Mankoff DA, Mulugeta P, Taunk NK.: Safety of the Combination of External Beam Radiotherapy with (177)Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer. J Nucl Med Sep 2025.

Likasitwatanakul P, Besonen C, Tsai AK, Sadeghipour N, Elliott A, Arafa AT, Passow R, Chesner L, Felices M, Kennedy PR, Patnaik A, Narayan V, Hamrick J, Sena LA, Zorko NA, Hwang JH, Antonarakis ES.: HLA class I expression shapes the tumor immune microenvironment and influences prognosis in prostate cancer. Prostate Cancer Prostatic Dis Oct 2025 Notes: doi: 10.1038/s41391-025-01045-9.

Xia C, Smith AM, Lefebvre B, Jamal FA, Armenian SH, Koropeckyj-Cox D, Zhang L, Liu PP, Landsburg D, Clark AS, Shah PD, Hubbard RA, Huang A, Golec S, Hewitt M, Wilcox NS, Chen Z, Rethy L, Jung W, Ko K, Narayan V, Martei YM, Lang NN, Januzzi JL, Felker GM, Ky B.: Biomarker-Guided Cardioprotection for Patients Treated With Anthracyclines A Randomized Clinical Trial. JAMA Netw Open 8(12 ): e2546201, Dec 2025.

Jung W, Ko K, Smith AM, Huang A, Xia C, Martei YM, Narayan V, Clark AS, Lefebvre B, McDermott K, Koropeckyj-Cox D, Fasan O, Hutsell A, Daniels A, Englefield V, Leger KJ, Getz KD, Narayan HK, Marshall JD, Powell-Wiley TM, Yancy CW, Ky B.: Air Pollution and Cardiac Remodeling and Function in Patients With Breast Cancer. JAMA Netw Open 9(1): e2552323. doi: 10.1001/jamanetworkopen.2025.52323. Jan 2026.

Litt, HK.; Wodzinski, A.; Subramanian, P.; Donovan, M.; Vapiwala, N.; Narayan, V.; Mei, L.; Takvorian, S.; Haas, NB.; Parikh, RB.; Mistry, R.; Mamtani, R.: OncoEducate: A Pilot Study of Generative AI to Enhance Patient-Clinician Communication in Genitourinary Cancer Care. Oncologist 31(5), Apr 2026.

Mo, G.; Narayan, V.: Novel Immunotherapies for Prostate Cancer. Urol Oncol 15, Apr 2026.

Makovec A, Gustafson A, Gandhi N, Rampalli S, Arafa AT, Elliott A, Smith N, Felices M, Kennedy PR, Shenderov E, Patnaik A, Narayan V, Heath EI, Zorko N, Shi X, Antonarakis ES, McKay RR, Hwang J.: B7-H3 Gene Expression Shapes Prognosis and Therapeutic Opportunities Across Prostate Cancer Patient Groups. Clin Cancer Res Page: doi: 10.1158, Apr 2026.

Saxena A, Yorker M, Zorko NA, Narayan V, Siddiqui BA, Saraiya B, Tester WJ, Mille PJ, Shaver AL, Nikita N, Lu-Yao GL, Kelly WK, Zarrabi KK.: Prevalence of adverse events following T-cell redirecting therapies in patients with metastatic castrate-resistant prostate cancer: a pooled analysis. Oncologist May 2026 Notes: doi: 10.1093/oncolo/oyag172.

Ky B, Liu T, Margulies KB, Mitchell JD, Haas NB, Gareen IF, Thangarajah M, Sicks JD, Domenico C, Narayan V, Smith AM, Wilcox NS, Mittal K, Rhee J, Armenian S, Saphner T, Paul AK, Gartrell BA, Zaha VG, Anari F, Wong RL, Townsend RR, Wagner L.: Cluster Randomized Trial of Intensive Systolic Blood Pressure Control in Patients With Renal Cell or Thyroid Cancer Receiving VEGFR Tyrosine Kinase Inhibitors: ECOG-ACRIN EAQ191. Hypertension May 2026 Notes: doi: 10.1161/HYPERTENSIONAHA.125.26016.